A.02. DHA JA FAR Part 13.5- RFO reference changes 7.30 - redacted

CUI//PROCURE

Control Number: FY26-0564
Justification and Approval (J&A) for Other than Full and Open Competition Revolutionary Federal Acquisition Regulation (FAR) Overhaul (RFO) Parts 6 and 12 Implemented by Class Deviation 2026-O0017, Revision 1
1. Identification of the Agency and Contracting Activity: Defense Health Agency (DHA) Contracting Activity (DHACA), Research and Development , Contracting Division 1, Contracting Branch 1, 808 Schreider Street, Fort Detrick, MD 21702-5014. 2. Nature and/or Description of Action being Approved: This is a follow-on materiel requirement, standalone, firm fixed price (FFP), best value/sole source contract. 3. Description of Supplies/Services: The contractor shall provide all Sentosa sequencer kits, consumables, supplies, sequencing systems and sub-components, and maintenance and repair as specified in the Minimum Essential Characteristics (MECs). The human immunodeficiency virus (HIV) Diagnostics and Reference Lab (HDRL), Diagnostics and Countermeasures Branch (DCB) at the Walter Reed Army Institute of Research (WRAIR) currently utilizes the Sentosa SQ Next Generation Sequencing (NGS) system in order to perform HIV genotype testing which is critical for the monitoring of drug resistance mutations in HIV-1 infected soldiers and their beneficiaries. The Sentosa NGS system includes instrumentation and reagents required to perform the Vela Sentosa SQ HIV-1 Genotype test in a College of American Pathologist (CAP) accredited laboratory. As the system and assay is Food and Drug Administration (FDA) approved, clinical testing laboratories are required to use the instruments and reagents approved by the FDA in the execution of the test. This requirement is to establish a follow-on contract to purchase Sentosa brand sequencer kits and consumables. With the purchases of the consumables, the vendor shall provide DCB with use of Sentosa NGS systems and subcomponents. In addition, the vendor shall maintain the systems to ensure instruments meet and maintain CAP standards for clinical testing operations. Period
Base
Option Period One
Option Period Two
Option Period Three
Option Period Four
Total

Period of Performance
September 30, 2026 – September 29, 2027
September 30, 2027 – September 29, 2028
September 30, 2028 – September 29, 2029
September 30, 2029 – September 29, 2030
September 30, 2030 – September 29, 2031

Estimated Value
$383,378.38
$394,879.73
$406,726.12
$418,927.91
$431,495.74